HERZELIA, Israel, July 2, 2024 /PRNewswire/ -- Endospan Ltd ("Endospan"), an Israeli-based, privately-held developer of the NEXUS^® Stent Graft System ("NEXUS"), announced today an agreement with Artivion, Inc ("Artivion") for additional loans of up to $25M for U.S. Food and Drug Administration ("FDA") approval of NEXUS.

"We're excited to progress in our IDE study with the FDA and extending options for more patients with aortic arch disease through this agreement with Artivion," Kevin Mayberry, chief executive officer of Endospan, said. "We share a commitment with Artivion to delivering minimally-invasive solutions to help surgeons address the complex challenges of this growing market."

More than 120,000 patients suffer thoracic aortic arch disease every year in the USA and Europe, with only about 25% diagnosed or treated. Despite significant advancements, open surgical aortic arch repair maintains high mortality and morbidity. Patients with excessive perioperative risk or anatomical factors are not indicated for surgery, yet anatomical complexity and lack of approved devices for the arch has often prohibited endovascular repair. This makes the choice of treatment difficult or even impossible for some patients. Providing the alternative of minimally invasive repair decreases the requirement for extra corporal circulation and the possibility of hypothermia, translating into reduced procedure and hospitalization time.

Endospan has developed NEXUS, the first and only approved branched endovascular system to treat aortic arch disease, including both aortic aneurysms and aortic dissections. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA) and Thoracic Aortic Aneurysm (TAA), aortic arch disease patients with aneurysms or dissections who receive treatment have previously had little choice but to undergo open-chest surgery with its associated invasiveness and risks, lengthy hospitalizations, and prolonged recuperation. NEXUS transforms a complex surgical aortic arch repair into a minimally invasive endovascular procedure. NEXUS addresses a $600M global addressable market opportunity.

Endospan is currently enrolling patients in the TRIOMPHE IDE Study, a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of NEXUS® in treating thoracic aortic lesions involving the aortic arch. The study will enroll up to 110 patients at up to 31 sites. Earlier this year, Endospan shared 30-day results of the first 22 patients enrolled in the study. This early data aligned with results achieved during an EU clinical study, suggesting that NEXUS may provide surgeons with a straightforward, minimally invasive solution for aortic arch repair that allows for procedural consistency with reliable patient outcomes.

About Endospan Ltd.
Privately held Endospan, headquartered in Herzelia (Tel Aviv), Israel, is a pioneer in the endovascular repair of Aortic Arch Disease including aneurysms and dissections. Endospan has received CE-Mark to commercialize in Europe the NEXUS™ Stent Graft System, the first endovascular off-the-shelf system to treat aortic arch disease which affects a greatly underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), aortic arch disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website, www.endospan.com.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Endospan
Kevin Mayberry
Chief Financial Officer
Kevin@endospan.com

Logo - https://mma.prnewswire.com/media/2452280/Endospan_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/endospan-receives-additional-25m-from-artivion-for-nexus-fda-approval-path-302188027.html

Images

Tags

More Like This

ONE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR ENDOTRONIX CORDELLA PULMONARY ARTERY SENSOR SYSTEM

Endotronix Submits PMA Application for its Cordella Pulmonary Artery Sensor System

GORE ANNOUNCES MDR EXPANDED INDICATION FOR THE GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS AS A BRIDGING STENT

Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial

Nitinotes Announces FDA IDE Approval to Initiate Pivotal U.S. Trial of the EndoZip™ System for Endoscopic Sleeve Gastroplasty

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Apollo Endosurgery obtains landmark CE marking for its bariatric treatments

Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt